Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 29

Related Articles by Review for PubMed (Select 21480237)

1.

Cancer therapy based on oncogene addiction.

McCormick F.

J Surg Oncol. 2011 May 1;103(6):464-7. doi: 10.1002/jso.21749. Review.

PMID:
21480237
2.

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Roberts PJ, Der CJ.

Oncogene. 2007 May 14;26(22):3291-310. Review.

PMID:
17496923
3.

The evolution of melanoma resistance reveals therapeutic opportunities.

Das Thakur M, Stuart DD.

Cancer Res. 2013 Oct 15;73(20):6106-10. doi: 10.1158/0008-5472.CAN-13-1633. Epub 2013 Oct 4. Review.

4.

Novel targets in solid tumors: MEK inhibitors.

Messersmith WA, Hidalgo M, Carducci M, Eckhardt SG.

Clin Adv Hematol Oncol. 2006 Nov;4(11):831-6. Review.

PMID:
17143253
5.

Novel mitogen-activated protein kinase kinase inhibitors.

Chapman MS, Miner JN.

Expert Opin Investig Drugs. 2011 Feb;20(2):209-20. doi: 10.1517/13543784.2011.548803. Review.

PMID:
21235429
6.

MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.

Sebolt-Leopold JS.

Curr Pharm Des. 2004;10(16):1907-14. Review.

PMID:
15180527
7.

Targeting the RAF-MEK-ERK pathway in cancer therapy.

Montagut C, Settleman J.

Cancer Lett. 2009 Oct 8;283(2):125-34. doi: 10.1016/j.canlet.2009.01.022. Epub 2009 Feb 12. Review.

PMID:
19217204
8.

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies.

Lee JT Jr, McCubrey JA.

Expert Opin Ther Targets. 2002 Dec;6(6):659-78. Review.

PMID:
12472379
9.

Raf: a strategic target for therapeutic development against cancer.

Beeram M, Patnaik A, Rowinsky EK.

J Clin Oncol. 2005 Sep 20;23(27):6771-90. Review.

PMID:
16170185
10.

Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.

Sullivan RJ, Atkins MB.

Expert Opin Investig Drugs. 2010 Oct;19(10):1205-16. doi: 10.1517/13543784.2010.504709. Review.

PMID:
20687784
11.

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade.

Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF.

Recent Prog Horm Res. 2001;56:127-55. Review.

PMID:
11237210
12.

MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression.

Johnson GL, Dohlman HG, Graves LM.

Curr Opin Chem Biol. 2005 Jun;9(3):325-31. Review.

PMID:
15939336
13.

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

Faivre S, Djelloul S, Raymond E.

Semin Oncol. 2006 Aug;33(4):407-20. Review.

PMID:
16890796
14.

Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.

Gollob JA, Wilhelm S, Carter C, Kelley SL.

Semin Oncol. 2006 Aug;33(4):392-406. Review.

PMID:
16890795
15.

Point mutations of protein kinases and individualised cancer therapy.

Davies M, Hennessy B, Mills GB.

Expert Opin Pharmacother. 2006 Nov;7(16):2243-61. Review.

PMID:
17059381
17.

Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.

Lambert PJ, Shahrier AZ, Whitman AG, Dyson OF, Reber AJ, McCubrey JA, Akula SM.

Expert Opin Ther Targets. 2007 May;11(5):589-99. Review.

PMID:
17465719
18.

Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.

Shapiro P.

Crit Rev Clin Lab Sci. 2002 Sep;39(4-5):285-330. Review.

PMID:
12385501
19.

Targeting the ERK signaling pathway in cancer therapy.

Kohno M, Pouyssegur J.

Ann Med. 2006;38(3):200-11. Review.

PMID:
16720434
20.

Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.

Bagrodia S, Smeal T, Abraham RT.

Pigment Cell Melanoma Res. 2012 Nov;25(6):819-31. doi: 10.1111/pcmr.12007. Epub 2012 Sep 14. Review.

PMID:
22883054
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk